Company news

Argenica Therapeutics Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Phase 2 Manufacturing Completed & Trial Update

February 11, 2024

Appointment of Non-Executive Chair

November 29, 2023

FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment

November 15, 2023

Argenica Receives $2.09m R&D Tax Incentive Cash Rebate

November 12, 2023

ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study

November 2, 2023

Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy

October 17, 2023

Ethics Approval Received for Phase 2 Trial

September 11, 2023

Grant Awarded To Develop Additional Administration Route

September 11, 2023

Positive FDA Feedback Following Pre-Ind Meeting

August 22, 2023

Appendix 4E & Annual Report 30 June 2023

August 22, 2023

Response to ASX Aware Query

August 18, 2023

ARG-007 Prevents Uptake & Aggregation of Key Protein

July 31, 2023

Investor Presentation

July 24, 2023

ARG-007 Phase 2 Clinical Trial Update

July 18, 2023

ARG-007 Protects Brain Cells in Moderate TBI Model

June 21, 2023

Argenica Successfully Completes $4.0m Placement

June 1, 2023

Final Phase1 Clinical Trial Report

May 14, 2023

Latest Preclinical HIE Study Results

April 19, 2023

Significant Non-Dilutive Funding For Preclinical HIE Studies

March 29, 2023

Interim Phase 1 Safety Report Confirms Safety of ARG-007

March 5, 2023

Non-Dilutive Funding Received to Progress Alzheimers Studies

February 21, 2023

Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers

February 8, 2023

Argenica Awarded $1.2m CRC-P Grant for TBI Project

January 19, 2023

Successful Completion of Phase 1 Clinical Trial Dosing

December 20, 2022

SRC Approves Commencement Of Fourth And Final Cohort Dosing

December 7, 2022

Phase 1 Clinical Trial Progress Update

November 24, 2022

Safety Review Committee Approves Third Cohort Commencement

November 17, 2022

Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

November 6, 2022

Safety Review Committee Approves Second Cohort

November 1, 2022

No Serious Safety Issues Observed in First Cohort

October 25, 2022

First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

October 16, 2022

Argenica Receives $1.38m R&D Tax Incentive Cash Refund

October 3, 2022

Further Positive Preclinical Results for ARG-007 In HIE

September 28, 2022

Argenica Receives Ethics Approval To Commence Phase 1 Trial

September 6, 2022

Appendix 4E & Annual Report 30 June 2022

August 23, 2022

Peer Reviewed Paper Published on Preclinical Safety Study

July 6, 2022

Application for quotation of securities - AGN

June 9, 2022

Argenica Successfully Completes $5.5m Placement

June 3, 2022

Argenica Therapeutics: Proposed issue of securities - AGN

June 2, 2022

Successful Completion of Final Pre-Clinical PK Study

May 18, 2022

GLP Safety Studies Successfully Completed

May 4, 2022

Maximum Tolerated Dose Successfully Established in Studies

April 25, 2022

Argenica Appoints CEO Dr Liz Dallimore Managing Director

April 3, 2022

Positive Preclincal Data on Efficacy in New Indication

March 29, 2022

Peer Reviewed Paper Published on Preclinical Study

March 20, 2022

Successful Completion of Final GLP Genotoxicity Studies

February 23, 2022

Preliminary Pre-Clinical Tox Studies Successfully Completed

January 23, 2022

Argenica to be Granted Patent Protection in the US

December 8, 2021

Positive Preclinical Data for ARG-007 Neuroprotection in HIE

November 2, 2021

Phase 1 Clinical Trial Overview & Roadmap

October 17, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 28 decks. Every deck is listed under its year.